Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8171684 | 0.84 | NOS3 (0.52) | NOS3NOS1NOS2SMN1; SMN2PIK3CB | |
| SCHEMBL31332287 | 0.84 | NOS3 (0.52) | NOS3NOS1NOS2SMN1; SMN2PIK3CB | |
| SCHEMBL1019253 | 0.84 | PIK3CB (0.55) | NOS3NOS1NOS2PIK3CBPARP1 | |
| SCHEMBL15081394 | 0.82 | SMN1; SMN2 (0.39) | NOS3NOS1NOS2SMN1; SMN2PIK3CB | |
| SCHEMBL15606575 | 0.80 | NOS3 (0.52) | NOS3NOS1NOS2SMN1; SMN2PIK3CB | |
| SCHEMBL25722645 | 0.80 | NOS3 (0.52) | NOS3NOS1NOS2PIK3CBPARP1 | |
| SCHEMBL24576946 | 0.79 | PIK3C3 (0.49) | NOS3NOS1NOS2PIK3CBPARP1 | |
| SCHEMBL17382219 | 0.79 | PIK3C3 (0.50) | NOS3NOS1NOS2PIK3CBPARP1 | |
| SCHEMBL17382217 | 0.79 | ATM (0.47) | NOS3NOS1NOS2IKBKETBK1 | |
| SCHEMBL6626587 | 0.79 | SMN1; SMN2 (0.56) | NOS3NOS1NOS2SMN1; SMN2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104592222-A | Preparation method for antiplatelet medicine AZD6482 | SUZHOU MIRACPHARMA TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | claimed |
| EP-4605400-A1 | NOVEL TRIHETEROCYCLIC COMPOUNDS | Idience Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024085661-A1 | NOVEL TRIHETEROCYCLIC COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024085661-A1 | NOVEL TRIHETEROCYCLIC COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | NOS3 3044/4885NOS1 3870/4885NOS2 3616/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | NOS3 3238/4885NOS1 3452/4885NOS2 3298/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | NOS3 4072/4885NOS1 4196/4885NOS2 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.